What Is Tirzepatide?

1. What Is Tirzepatide?

Tirzepatide is the active ingredient in Mounjaro and Zepbound. The current DailyMed Mounjaro label and DailyMed Zepbound label describe it as a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist.

That phrase is technical, but it answers a common naming problem. Tirzepatide is not itself “Mounjaro” or “Zepbound.” It is the molecule inside those branded prescription products. The brand name tells you which product label you are talking about. The molecule name tells you the active ingredient. The receptor-language phrase tells you how the label classifies the drug at a high level.

This matters because public shorthand often collapses all of those facts into one word. Someone might say “tirzepatide,” “Mounjaro,” “Zepbound,” “GLP-1,” “weight-loss shot,” or “diabetes drug” as if the terms are interchangeable. They overlap, but they do not mean the same thing.

2. Why Is Tirzepatide Called Dual GIP/GLP-1?

Tirzepatide is called dual GIP/GLP-1 because the current Mounjaro and Zepbound labels say tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors. That makes “dual GIP and GLP-1 receptor agonist” more precise than calling it only a GLP-1 medication.

GLP-1 is the familiar public term because medications such as semaglutide made “GLP-1” part of everyday health news. GIP is another incretin-related hormone pathway. Tirzepatide sits in the same broad conversation because it includes GLP-1 receptor activity, but the label language includes both receptors.

The distinction is more than trivia. A broad phrase like “GLP-1 drugs” may be useful in headlines, but it hides differences between molecules. Semaglutide and tirzepatide are not the same active ingredient. A brand label and a mechanism description are also different types of information. For broader background, see What Is a GLP-1?.

3. How Is Tirzepatide Related to Mounjaro?

Mounjaro is a brand name for tirzepatide. The current DailyMed Mounjaro label says Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.

FDA’s Drug Trials Snapshot for Mounjaro says the agency approved Mounjaro based on evidence from nine clinical trials of 7,769 patients with type 2 diabetes mellitus. That source is useful because it anchors Mounjaro in its original type 2 diabetes approval context, rather than in later public weight-loss conversation.

The clean wording is: Mounjaro contains tirzepatide and has a type 2 diabetes glycemic-control label context. That does not answer product choice, use, or switching questions for any person. It only separates the brand from the molecule and the label.

For a brand-specific explainer, see What Is Mounjaro?. For recordkeeping rather than medication advice, see Mounjaro Tracker App.

4. How Is Tirzepatide Related to Zepbound?

Zepbound is also a brand name for tirzepatide. The current DailyMed Zepbound label lists two high-level U.S. contexts: reducing excess body weight and maintaining weight reduction long term in adults with obesity or certain adults with overweight, and treating moderate to severe obstructive sleep apnea in adults with obesity.

FDA’s November 2023 chronic weight-management approval announcement stated that tirzepatide, Zepbound’s active ingredient, was already approved under the trade name Mounjaro for adults with type 2 diabetes. FDA’s December 2024 OSA approval announcement later described Zepbound as approved for moderate to severe obstructive sleep apnea in adults with obesity, used with reduced-calorie diet and increased physical activity.

That is why “same active ingredient” is true but incomplete. Mounjaro and Zepbound both contain tirzepatide. Their brand names, labeled populations, public contexts, and recordkeeping needs are not identical.

For the brand-specific page, see What Is Zepbound?. For neutral records rather than product selection, see Zepbound Tracker App or Tirzepatide Tracker App.

5. Molecule, Brand, and Label Are Separate Facts

The most useful way to understand tirzepatide is to keep three layers separate: molecule, brand, and label. The molecule is tirzepatide. The U.S. brand may be Mounjaro or Zepbound. The label context depends on which brand and which current prescribing information you are reading.

This separation prevents several common mistakes. It avoids treating “tirzepatide” as if it were one brand. It avoids treating “Mounjaro” and “Zepbound” as interchangeable public names. It avoids treating “GLP-1” as the full mechanism description. And it avoids turning a label fact into personal medical advice.

6. Why the Distinction Matters in Real Life

The distinction matters because labels change, brand names carry regulatory context, and public conversation often moves faster than careful wording. DailyMed shows recent label updates for both Mounjaro and Zepbound, which is a reminder that current prescribing information is stronger than memory or social shorthand.

There are practical recordkeeping reasons too. A note that says “GLP-1” may not say which active ingredient, which brand, which indication context, or which source was used. A clearer record separates those details:

• Active ingredient: tirzepatide
• Brand name: Mounjaro or Zepbound
• Label context: type 2 diabetes, chronic weight management, or OSA
• Source checked: current label, FDA announcement, or another high-quality source
• Boundary: education and records, not treatment instructions

That kind of precision is useful for reading news, organizing personal records, or understanding a prescription label. It does not turn a naming record into a product-comparison or use decision.

7. Sources

8. What Is Tirzepatide FAQ

• What is tirzepatide in simple terms?

  Tirzepatide is an active ingredient used in prescription medicines including Mounjaro and Zepbound. Current U.S. labels describe it as a GIP receptor and GLP-1 receptor agonist, which is why it is often discussed with GLP-1 medications.

• Is tirzepatide the same as Mounjaro or Zepbound?

  No. Tirzepatide is the active ingredient. Mounjaro and Zepbound are brand names with different U.S. label contexts. Mounjaro is labeled for type 2 diabetes glycemic control, while Zepbound is labeled for chronic weight management and certain OSA use.

• Why is tirzepatide called a dual GIP/GLP-1 receptor agonist?

  The Mounjaro and Zepbound labels state that tirzepatide selectively binds to and activates both GIP and GLP-1 receptors. That receptor wording is more precise than calling tirzepatide only a GLP-1 drug.

• Is tirzepatide approved for diabetes, weight management, or OSA?

  The answer depends on the brand label. Mounjaro is the tirzepatide brand labeled for type 2 diabetes glycemic control. Zepbound is the tirzepatide brand labeled for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity.